Promoter and Institutional shareholding for Beryl Drugs remained unchanged, indicating a lack of conviction from smart money.

Public shareholding decreased by 2.21% YoY and 0.71% QoQ, suggesting retail investors are losing interest in the stock.

In contrast, the sector averages show no significant changes, highlighting Beryl's relative underperformance compared to peers.